JP2021513367A - 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体 - Google Patents

改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体 Download PDF

Info

Publication number
JP2021513367A
JP2021513367A JP2020565253A JP2020565253A JP2021513367A JP 2021513367 A JP2021513367 A JP 2021513367A JP 2020565253 A JP2020565253 A JP 2020565253A JP 2020565253 A JP2020565253 A JP 2020565253A JP 2021513367 A JP2021513367 A JP 2021513367A
Authority
JP
Japan
Prior art keywords
antibody
cells
antigen
sequence
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020565253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513367A5 (https=
Inventor
アントン エグバート ペーター アダング，
アントン エグバート ペーター アダング，
ブール， マルク デ
ブール， マルク デ
Original Assignee
ダイアベーツ−フリー， インコーポレイテッド
ダイアベーツ−フリー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダイアベーツ−フリー， インコーポレイテッド, ダイアベーツ−フリー， インコーポレイテッド filed Critical ダイアベーツ−フリー， インコーポレイテッド
Publication of JP2021513367A publication Critical patent/JP2021513367A/ja
Publication of JP2021513367A5 publication Critical patent/JP2021513367A5/ja
Priority to JP2024002623A priority Critical patent/JP2024024118A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020565253A 2018-02-12 2019-02-11 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体 Pending JP2021513367A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024002623A JP2024024118A (ja) 2018-02-12 2024-01-11 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18156288 2018-02-12
EP18156288.5 2018-02-12
PCT/NL2019/050086 WO2019156565A1 (en) 2018-02-12 2019-02-11 Improved antagonistic anti-human cd40 monoclonal antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024002623A Division JP2024024118A (ja) 2018-02-12 2024-01-11 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体

Publications (2)

Publication Number Publication Date
JP2021513367A true JP2021513367A (ja) 2021-05-27
JP2021513367A5 JP2021513367A5 (https=) 2022-02-21

Family

ID=61192786

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020565253A Pending JP2021513367A (ja) 2018-02-12 2019-02-11 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体
JP2024002623A Pending JP2024024118A (ja) 2018-02-12 2024-01-11 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024002623A Pending JP2024024118A (ja) 2018-02-12 2024-01-11 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体

Country Status (8)

Country Link
US (2) US11396552B2 (https=)
EP (1) EP3752532A1 (https=)
JP (2) JP2021513367A (https=)
KR (1) KR20200141986A (https=)
CN (1) CN112119092A (https=)
AU (1) AU2019217207B2 (https=)
CA (1) CA3090322A1 (https=)
WO (1) WO2019156565A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
JP2021513367A (ja) * 2018-02-12 2021-05-27 ダイアベーツ−フリー， インコーポレイテッド 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体
CN115605594A (zh) * 2020-06-02 2023-01-13 帝人制药株式会社（Jp） 抗igf-1受体人源化抗体
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
CN115403670B (zh) * 2021-05-26 2026-03-10 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
WO2025122817A1 (en) * 2023-12-06 2025-06-12 The General Hospital Corporation Antagonistic cd40 antibodies
KR20250116195A (ko) * 2024-01-24 2025-08-01 서울대학교산학협력단 Cd40에 특이적으로 결합하는 항체 및 이의 용도
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512243A (ja) * 2003-11-04 2007-05-17 カイロン コーポレイション Ｃｄ４０抗原を発現する癌に対する治療方法。
JP2009536522A (ja) * 2006-05-09 2009-10-15 パンジェネティクス ビー．ブイ． 拮抗性抗ヒトｃｄ４０モノクローナル抗体
JP2013523130A (ja) * 2010-03-31 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｃｄ４０抗体
WO2016196314A1 (en) * 2015-05-29 2016-12-08 Abbvie Inc. Anti-cd40 antibodies and uses thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4747825A (en) 1984-06-29 1988-05-31 Ferring Laboratories, Inc. Apparatus and methodology for pulsed administration of growth promoting agents
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1178786B (it) 1984-12-21 1987-09-16 Assorenti Analoghi retro-inverso parzialmente modificati della neurotensina
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
US4723958A (en) 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4965251A (en) 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU649217B2 (en) 1988-11-18 1994-05-19 Regents Of The University Of California, The Method for site-specifically incorporating unnatural amino acids into proteins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
HUT71860A (en) 1992-08-27 1996-02-28 Deakin Res Ltd Retro-, inverso-, and retro-inverso synthetic peptide analogues
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5403590A (en) 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6339069B1 (en) 1996-10-15 2002-01-15 Elan Pharmaceuticalstechnologies, Inc. Peptide-lipid conjugates, liposomes and lipsomal drug delivery
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6103489A (en) 1997-03-21 2000-08-15 University Of Hawaii Cell-free protein synthesis system with protein translocation and processing
CA2303268A1 (en) 1997-06-13 1998-12-17 Scott Walsh Therapeutic nanospheres
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
FR2840307B1 (fr) 2002-05-30 2006-07-07 Centre Nat Rech Scient Nouvelles molecules multimeriques, leur procede de preparation, et leur utilisation pour la preparation de medicaments
WO2005006949A2 (en) 2003-07-07 2005-01-27 Wagner David H Methods for predicting development of auto-immune diseases and treatment of same
US20080318837A1 (en) 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US7659252B2 (en) 2005-09-15 2010-02-09 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
US20070237826A1 (en) 2006-04-05 2007-10-11 Rao Kollipara K Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides
AR060487A1 (es) * 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
EP2067785A1 (en) 2007-12-03 2009-06-10 Fresenius Medical Care Deutschland GmbH Human CD154-binding synthetic peptide and uses thereof
US8734786B2 (en) 2009-09-16 2014-05-27 Northwestern University Use of ECDI-fixed cell tolerance as a method for preventing allograft rejection
WO2011069037A2 (en) 2009-12-03 2011-06-09 The University Of North Carolina At Charlotte Stabilization and storage of biological pharmaceutical compositions
ES2957957T3 (es) 2010-10-19 2024-01-30 Op T Llc Péptidos para modular la actividad de linfocitos T y usos de los mismos
TR201909840T4 (tr) 2011-03-11 2019-07-22 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antikorları ve kullanımları.
CA2832281C (en) 2011-04-04 2019-11-05 Trustees Of Dartmouth College Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies
WO2012145632A1 (en) 2011-04-21 2012-10-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
KR101329411B1 (ko) 2012-05-31 2013-11-14 주식회사 엘지생활건강 피부투과성 펩타이드
EP3701969A1 (en) 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
US20180172683A1 (en) 2015-06-22 2018-06-21 University Of Southern California Methods for analyzing the interaction between a target protein and a ligand
KR101810778B1 (ko) 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
JP2021513367A (ja) * 2018-02-12 2021-05-27 ダイアベーツ−フリー， インコーポレイテッド 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512243A (ja) * 2003-11-04 2007-05-17 カイロン コーポレイション Ｃｄ４０抗原を発現する癌に対する治療方法。
JP2009536522A (ja) * 2006-05-09 2009-10-15 パンジェネティクス ビー．ブイ． 拮抗性抗ヒトｃｄ４０モノクローナル抗体
JP2013523130A (ja) * 2010-03-31 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｃｄ４０抗体
WO2016196314A1 (en) * 2015-05-29 2016-12-08 Abbvie Inc. Anti-cd40 antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF HAEMATOLOGY, vol. 159, JPN6023001055, 2012, pages 58 - 66, ISSN: 0004963857 *

Also Published As

Publication number Publication date
US11396552B2 (en) 2022-07-26
KR20200141986A (ko) 2020-12-21
AU2019217207A1 (en) 2020-08-27
US20230059094A1 (en) 2023-02-23
AU2019217207B2 (en) 2025-12-18
JP2024024118A (ja) 2024-02-21
CA3090322A1 (en) 2019-08-15
US20210101991A1 (en) 2021-04-08
CN112119092A (zh) 2020-12-22
WO2019156565A1 (en) 2019-08-15
EP3752532A1 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
US11396552B2 (en) Antagonistic anti-human CD40 monoclonal antibodies
US20230201346A1 (en) Binding molecules specific for il-21 and uses thereof
JP2017512772A (ja) Ｌｇ１〜３に特異的な抗ラミニン４抗体
WO2021143914A1 (zh) 一种激活型抗ox40抗体、生产方法及应用
US20240182594A1 (en) Uses of antagonist, non-depleting ox40 antibodies
US20250270328A1 (en) Klrb1 binding agents and methods of use thereof
WO2026056853A1 (zh) Tl1a抗体及其应用
WO2025214468A1 (zh) 抗il-15抗体以及其用途
WO2026056850A1 (zh) Tl1a单域抗体及其应用
RU2804456C1 (ru) Связывающие молекулы, специфичные к ил-21, и области их применения
AU2024322975A1 (en) Anti-ox40l antibody and use thereof
CN120590530A (zh) 靶向tl1a的抗体及其应用
HK1230976B (en) Binding molecules specific for il-21 and uses thereof
HK1230976A1 (en) Binding molecules specific for il-21 and uses thereof
NZ725735B2 (en) Binding molecules specific for il-21 and uses thereof
NZ762893B2 (en) Binding molecules specific for il-21 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240111

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240219

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240412